Default company panoramic image
234fffd2 dc44 4ca2 9884 55810bb73a59

Regenesis Biomedical Inc.

FDA-cleared medical device: $20+ million run rate and cash positive; re-investing in sales, operations and clinical; and expanding payers

  • Stage $20M in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Scottsdale, AZ, USA
  • Currency USD
  • Founded March 1997
  • Employees 85
  • Website

Company Summary

Regenesis is a private medical technology company focused on developing and marketing tissue regenerative medicine products. Regenesis developed, patented, and now markets the Provant® Therapy System. Customers include health care facilities and providers that serve patients treated in hospitals, long-term acute care, skilled nursing facilities, rehabilitation centers, and outpatient clinics as well as by patients in their homes.


  • Default avatar
    Rick Isenberg, MD
    VP Clinical/Regulatory

    Dr. Isenberg served on the medical faculties of the University of Pennsylvania and Thomas Jefferson University and directed a fellowship program. While in industry, Dr. Isenberg held senior management positions at Johnson & Johnson (Ethicon, Inc), Wyeth Pharmaceuticals and Ventana Medical Systems.

  • Default avatar
    Virginia Shimer Rybski
    President, Chief Executive Officer & Director

    Ms. Rybski held senior management positions with Genex, Advanced Tissue Sciences, Unisyn Technologies and Millipore/Waters. Since 2011, Ms. Rybski serves on the Board of Directors for AdvaMed, the advanced medical technology association. Since early 2012, Ms. Rybski also serves on the Board of Directors for AZBIO, the Arizona biotechnology and medical device association.

  • Default avatar
    Dennis Genge
    VP Finance & Chief Financial Officer

    Mr. Genge held senior management positions with Novavax, Pyxis (a subsidiary of Cardinal Health), Ligand Pharmaceuticals, Ivonyx and IMED.

  • Default avatar
    Tom Eisiminger
    VP Sales

    Mr. Eisiminger is a retired United States Army Officer and decorated combat veteran. He joined Regenesis in 2006. Mr. Eisiminger held numerous leadership positions in the Army at every level from platoon to battalion command.

  • Default avatar
    Scott Robey
    VP Marketing

    Mr. Robey is a 21 year marketing veteran. Prior to Regenesis, he served at Kinetic Concepts, Inc (KCI) for the V.A.C. Therapy brand during the time US product sales grew from about $70M in 2000 to about $1 billion by 2007. He has held marketing positions at Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc).

  • Default avatar
    Adrianne (Patti) Smith MD
    VP Medical Affairs & Medical Director

    Dr. Smith was Vice President and Medical Director at Kinetic Concepts Inc. (KCI) providing medical support for clinicians using the wound V.A.C®, and Senior Medical Advisor at Diversified Clinical Services. Her academic appointments have included the University of Texas Health Science Center; the Chief of Emergency Services for Scott Air Force Base; and the Medical Director of the Texas Diabetes Institute.

  • Default avatar
    Scott Brooks
    Chief Operating Officer

    Prior to Regenesis, Mr. Brooks held the position of President of the U.S. and Canada for BSN Medical. Prior to BSN, Mr. Brooks was the VP of Sales and National Accounts for Kinetic Concepts Inc. (KCI), the global leader of advanced wound care devices. Scott’s experience includes leadership positions with The Hill-Rom Company and Kimberly-Clark Healthcare.

  • Default avatar
    Steve Soderberg
    VP, Operations

    Mr. Soderberg has served the Company since 1997. His first five years were coordinating external consultant projects; then in 2002 he joined the company full time. Mr. Soderberg has over 25 years in the high-tech Bio-Medical industry having covered critical management positions in five start-up bio-science companies, assuring their success. Operational management expertise includes Manufacturing, Materials Management, Research & Development, Sust


  • Default avatar
    Snell & Wilmer; Latham & Watkins; King & Spaulding; Morrison & Forester
    Default avatar
    Ernst & Young

Previous Investors

  • Default avatar
    Fulcrum, TGap, Solstice, Valley Ventures, Village Ventures,
    Default avatar
    Aztec Ventures, Desert Regenesis